EVP and Chief Medical Officer Laurence de Moerlooze Will Be Leaving Bavarian Nordic
2024年5月21日 - 9:00PM
EVP and Chief Medical Officer Laurence de Moerlooze Will Be Leaving
Bavarian Nordic
COPENHAGEN, Denmark, May 21,
2024 – Bavarian Nordic A/S (OMX: BAVA) today announced
that Laurence de Moerlooze will leave her position as Executive
Vice President and Chief Medical Officer in the Company to pursue
new opportunities. She will continue to support Bavarian Nordic
until the end of May 2024. The Company will initiate a search
process to identify the next Chief Medical Officer.
Paul Chaplin, President & CEO of Bavarian
Nordic, said: “On behalf of everyone at Bavarian Nordic, I want to
express my gratitude to Laurence for her significant contributions
to the company during our commercial transformation over the past
years. Laurence joined in 2020, tasked with building a development
function to support our growing commercial footprint. Through the
establishment of global medical, pharmacovigilance and regulatory
teams as well as a clinical organization purposed to drive
continued product lifecycle management and pipeline development,
these objectives have now been achieved, and Laurence will leave
the Company to look for new challenges. We wish her all the very
best in her future endeavors.”
About Bavarian NordicBavarian
Nordic is a fully integrated vaccine company with a mission to
protect and save lives through innovative vaccines. We are a global
leader in smallpox and mpox vaccines, supplied to governments to
enhance public health preparedness and have a strong portfolio of
vaccines for travelers and endemic diseases. For more information
visit www.bavarian-nordic.com.
Forward-looking statements This
announcement includes forward-looking statements that involve
risks, uncertainties and other factors, many of which are outside
of our control, that could cause actual results to differ
materially from the results discussed in the forward-looking
statements. Forward-looking statements include statements
concerning our plans, objectives, goals, future events, performance
and/or other information that is not historical information. All
such forward-looking statements are expressly qualified by these
cautionary statements and any other cautionary statements which may
accompany the forward-looking statements. We undertake no
obligation to publicly update or revise forward-looking statements
to reflect subsequent events or circumstances after the date made,
except as required by law.
ContactsEurope: Rolf Sass
Sørensen, Vice President Investor Relations,
rss@bavarian-nordic.com, Tel: +45 61 77 47 43US: Graham Morrell,
graham@paddockcircle.com, Tel: +1 781 686 9600
Company Announcement no. 14 / 2024
Bavarian Nordic AS (TG:BV3)
過去 株価チャート
から 5 2024 まで 6 2024
Bavarian Nordic AS (TG:BV3)
過去 株価チャート
から 6 2023 まで 6 2024